https://doi.org/10.4081/monaldi.2022.2226
Combined SCLC clinical and pathological aspects
Submitted: February 7, 2022
Accepted: May 31, 2022
Published: June 8, 2022
Accepted: May 31, 2022
Abstract Views: 821
PDF: 220
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Combined small cell lung carcinoma (C-SCLC) is rare and accounts for 1-3% of all lung cancer cases. Although its incidence has increased recently, there are limited studies on it. The records of patients admitted to our hospital between January 2015 and December 2019 and diagnosed with histologically proven combined small cell were scanned retrospectively and reviewed. 31 patients were analyzed. The average follow-up time was 10 months. The radiotherapy (RT) rate, surgery rate, and large cell malignancy rate were significantly lower in the ex group than in the living group (p=0.024, p=0.023, p=0.015). The rates of extensive disease, metastasis, and thyroid transcription factor 1 (TTF1) were significantly higher in the old group than in the living group (p=0.000, p=0.000, p=0.029, respectively). In the univariate model, sequential RT, fatigue, lactate dehydrogenase (LDH), stage, metastasis, contralateral lung metastasis, chemotherapy were observed to be significantly effective in predicting survival time (p=0.000, p=0.050, p=0.011, p=0.004, p=0.004, p=0.045, p=0.009). In the multivariate model, independent (p=0.015, p=0.022, p=0.049) efficacy of RT, stage, and chemotherapy in predicting survival was observed. C-SCLC is a specific mixed carcinoma and reports evaluating this type are still scarce. The stage of the disease, radiotherapy and chemotherapy are extremely important in predicting survival.
Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-96.
DOI: https://doi.org/10.1016/S0140-6736(05)67569-1
Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol 2012;25:S18–30.
DOI: https://doi.org/10.1038/modpathol.2011.150
Travis WD. The 2015 WHO classification of lung tumors. Pathologe 2014;35:s188.
DOI: https://doi.org/10.1007/s00292-014-1974-3
Trawis WD, Brambilla E, Müler-Hermelink K, et al. Tumors of the lung. In: World Health Organization classifications of tumors, pathology and genetics, tumors of the lung, pleura, thymus and heart. Lyon: IARC; 2004. p. 9-124.
Luo J, Ni J, Zheng H. Clinical analysis of 88 cases with combined small cell carcinoma. Zhong Liu 2009;29:156–9.
Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75:s191-202.
DOI: https://doi.org/10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y
van Meerbeeck JP, Fennell DA, De Ruysscher DKM. Small-cell lung cancer. Lancet 2011;378:1741–55.
DOI: https://doi.org/10.1016/S0140-6736(11)60165-7
Travis WD, Brambilla E, Burke AP, et al. WHO Classification of tumours of the lung, pleura, thymus and heart. 4th Ed. Geneva: WHO; 2015.
Babakoohi S, Fu P, Yang M, et al. Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer 2013;14:113–9.
DOI: https://doi.org/10.1016/j.cllc.2012.07.002
Luo Y, Hui Z, Yang L, et al. [Clinical analysis of 80 patients with combined small-cell lung cancer].[Article in Chinese]. Zhongguo Fei Ai Za Zhi 2015;18:161–6.
Zhang C, Yang H, Zhao H, et al. Clinical outcomes of surgically resected combined small cell lung cancer: a two-institutional experience. J Thorac Dis 2017;9:151–8.
DOI: https://doi.org/10.21037/jtd.2017.01.07
Wallace AS, Arya M, Frazier SR, et al. Combined small-cell lung carcinoma: an institutional experience. Thorac Cancer 2014;5:57–62.
DOI: https://doi.org/10.1111/1759-7714.12059
Lvu X, Sun LN, Zhan ZL, et al. [Clinicopathological characteristics and prognosis of combined small cell lung cancer].[Article in Chinese]. Zhongguo Zhong Liu Lin Chuang 2011;38:769–72.
Lantuejoul S, Fernandez-Cuesta L, Damiola F, et al. New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts. Transl Lung Cancer Res 2020;9:2233.
DOI: https://doi.org/10.21037/tlcr-20-269
Fraire AE, Johnson EH, Yesner R, et al. Prognostic significance of histopathologic subtype and stage in small cell lung cancer. Hum Pathol 1992;23:520–8.
DOI: https://doi.org/10.1016/0046-8177(92)90129-Q
Men Y, Hui Z, Liang J, et al. Further understanding of an uncommon disease of combined small cell lung cancer: clinical features and prognostic factors of 114 cases. Chin J Cancer Res 2016;28:486–94.
DOI: https://doi.org/10.21147/j.issn.1000-9604.2016.05.03
Goldstraw P. IASLC staging handbook in thoracic oncology. Editorial Rx Press; 2009.
Fushimi H, Kikui M, Morino H, et al. Histologic changes in small cell lung carcinoma after treatment. Cancer 1996;77:278-83.
DOI: https://doi.org/10.1002/(SICI)1097-0142(19960115)77:2<278::AID-CNCR9>3.0.CO;2-I
Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004;22:3248-54.
DOI: https://doi.org/10.1200/JCO.2004.11.089
Yan L, X Liu, YH Li, et al. Prognostic value of delta like protein 3 combined with thyroid transcription factor-1 in small-cell lung cancer. Oncol Lett 2019;18:2254-61.
DOI: https://doi.org/10.3892/ol.2019.10538
Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008;14:6092–6.
DOI: https://doi.org/10.1158/1078-0432.CCR-08-0332
Cooper S, Spiro SG. Small cell lung cancer. Treatment review. Respirology 2006;11:241-8.
DOI: https://doi.org/10.1111/j.1440-1843.2006.00850.x
Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer 2010;116:1350–7.
DOI: https://doi.org/10.1002/cncr.24853
Varlotto JM, Recht A, Flickinger JC, et al. Lobectomy leads to optimal survival in early-stage small cell lung cancer: a retrospective analysis. J Thorac Cardiovasc Surg 2011;142:538–46.
DOI: https://doi.org/10.1016/j.jtcvs.2010.11.062
Maestu I, Pastor M, Gomez-Codina J, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 1997;8:547-53.
DOI: https://doi.org/10.1023/A:1008212826956
How to Cite
Çimen, Filiz, Sevim Düzgün, and Sükran Atikcan. 2022. “Combined SCLC Clinical and Pathological Aspects”. Monaldi Archives for Chest Disease 93 (1). https://doi.org/10.4081/monaldi.2022.2226.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Yoldez Houcine, Chirine Moussa, Ahmed Ben Abdelaziz, Aida Ayadi, PDL1 and molecular biomarkers expression in non-small cell lung cancer in Tunisian patients , Monaldi Archives for Chest Disease: Early Access
- Mohammad Abu-Hishmeh, Laura Miranda, Fouzia Shakil, Tauseef Ahmed, Oleg Epelbaum, Hammering home the sickle: an instructive case of endobronchial anaplastic large cell lymphoma , Monaldi Archives for Chest Disease: Vol. 91 No. 3 (2021)
- Vinay V, Saraansh Bansal, Pallavi Purwar, Ravindra Kumar Dewan, Paras Verma, Shalini Mullick, Mallika Dixit, B Rama Phanindra , Kanishk Siddhartha, Thoracic follicular dendritic cell sarcoma - an outlandish presentation of a rare tumour with review of literature , Monaldi Archives for Chest Disease: Vol. 93 No. 2 (2023)
- Halil Yanardag, Cuneyt Tetikkurt, Muammer Bilir, Erkan Yılmaz, Association of HLA antigens with the clinical course of sarcoidosis and familial disease , Monaldi Archives for Chest Disease: Vol. 87 No. 3 (2017)
- Johanna Köhl, Floriana Bardaro, Emanuele Stirpe, An unexpected diagnosis of a lung mass with endobronchial involvement , Monaldi Archives for Chest Disease: Vol. 92 No. 4 (2022)
- A. Voulgaridis, V. Apollonatou, D. Lykouras, A. Giannopoulos, M. Iliopoulou, K. Karkoulias, P. Kraniotis, C. Prokakis, M. Gkermpesi, K. Spiropoulos, Pleural Mesothelioma in a young male patient , Monaldi Archives for Chest Disease: Vol. 79 No. 2 (2013): Pulmonary series
- G.V. Scagliotti, S. Novello, G. Selvaggi, Cytotoxic chemotherapy in advanced non-small cell lung cancer , Monaldi Archives for Chest Disease: Vol. 63 No. 4 (2005): Pulmonary series
- D. Lykouras, F. Sampsonas, A. Kaparianos, K. Karkoulias, G. Tsoukalas, K. Spiropoulos, Human genes in TB infection: their role in immune response , Monaldi Archives for Chest Disease: Vol. 69 No. 1 (2008): Pulmonary series
- Miguel Martins Carvalho, Ricardo Alves Pinto, Tânia Proença, Inês Costa, Nuno Tavares, Mariana Paiva, Carla Sousa, Filipe Macedo, Cardiovascular toxicity in breast cancer patients – contributors and role of cardioprotective drugs , Monaldi Archives for Chest Disease: Vol. 93 No. 4 (2023)
- A. Zanini, S. Della Patrona, A.L. Facchini, A. Spanevello, Induced sputum in the management of COPD: clinical implications , Monaldi Archives for Chest Disease: Vol. 77 No. 1 (2012): Pulmonary series
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
